Akèy › Maladi Crohn › Michigan
Etid klinik pou Maladi Crohn nan Michigan
20 etid pou Maladi Crohn ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
Tèks ofisyèl etid la (Anglè)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- St. Joseph Mercy Hospital - Huron Gastroenterology Associates ( Site 0287), Ypsilanti
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Michigan ( Site 5060), Ann Arbor
- Clinical Research Institute of Michigan, LLC ( Site 5002), Clinton Township
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- West Michigan Clinical Research Center /ID# 280480, Wyoming
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastroenterology Associates of Western Michigan, P.L.C., Wyoming
- Huron Gastro, Ypsilanti
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Henry Ford Medical Center - Columbus /ID# 266503, Novi
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Michigan Center of Medical Research, Farmington Hills
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07499232An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Henry Ford Medical Center - Columbus-Site Number: 8400118, Novi
- Gastroenterology Associates of Western Michigan-Site Number: 8400060, Wyoming
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center, Wyoming
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07483073A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center, Wyoming
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Huron Gastroenterology Associates, P.C., Ypsilanti
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Michigan Center of Medical Research, Farmington Hills
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07577843A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Children's Hospital of Michigan, Detroit
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Aug 3, 2026 · NCT06100289Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease
- University of Micigan, Ann Arbor
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT07456566A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Childrens Hospital of Michigan, Detroit
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Jun 22, 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- University of Michigan, Ann Arbor
Ap rekriteFaz 4
Laj 6 a 17 · Tout sèks · Mizajou May 27, 2026 · NCT05781152Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Henry Ford Columbus Center, Detroit
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Apr 27, 2026 · NCT06456593A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400008, Wyoming
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Mar 27, 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Ypsilanti
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Mar 12, 2026 · NCT07113522A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease
- University of Michigan, Ann Arbor
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jan 15, 2026 · NCT05849012Treatment of Moderate to Severe Refractory Crohn's Disease
- University of Michigan, Ann Arbor
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Dec 10, 2025 · NCT06721962Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.